The Role of KCa3.1 in Microglial function and in Parkinsons disease pathogenesis
KCa3.1 在小胶质细胞功能和帕金森病发病机制中的作用
基本信息
- 批准号:10445079
- 负责人:
- 金额:$ 38.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-15 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AblationAddressAdultAffectAutopsyBiological AssayBiological AvailabilityBrainBrain DiseasesCRISPR/Cas technologyCalciumCalcium SignalingCalcium-Activated Potassium ChannelCellsClinical TrialsDevelopmentDiseaseDisease ProgressionElectrophysiology (science)ExhibitsExperimental ModelsFYN geneFunctional disorderGenesHomeostasisHumanImageImmuneImpairmentIn Situ HybridizationInflammation MediatorsKnockout MiceLeadLinkMediatingMicrogliaMidbrain structureMissionMolecularMusNational Institute of Neurological Disorders and StrokeNatural ImmunityNerve DegenerationNeurodegenerative DisordersOralParkinson DiseaseParkinsonian DisordersPathogenesisPathologyPatientsPenetrancePharmacologyPhenotypePlayPotassiumPotassium ChannelPre-Clinical ModelProcessProgressive DiseaseRNAResearchRoleSTAT1 geneSafetySignal TransductionSocietiesTestingTherapeuticTimeTranscriptTransgenic OrganismsTreatment EfficacyUnited States National Institutes of HealthUp-Regulationalpha synucleinattenuationbaseconditional knockoutimmunomodulatory therapiesin vivoinflammatory modulationinhibitorinnovationinsightinterestmouse modelneurobehavioralneuroinflammationneuron lossneuroprotectionneurotoxicitynew therapeutic targetnovelnovel therapeutic interventionpre-clinicalprogressive neurodegenerationprotein expressionresponsesocioeconomicssynucleinopathytherapeutic evaluationtranscriptomics
项目摘要
Abstract
Recent studies have begun to uncover the central role of microglia-mediated neuroinflammation in Parkinson’s
disease (PD) pathogenesis. Increasing evidence suggests that microglia-driven innate immunity could further
potentiate deleterious α-synuclein (αSyn) aggregation and progressive neurodegeneration. However, we lack an
in-depth understanding of the cellular mechanisms regulating αSyn-induced innate immunity. Therefore,
identifying signaling mechanisms that regulate microglial function in response to Parkinsonian pathology may
lead to the development of novel immunomodulatory therapies for PD. We recently discovered that the transcript
and protein expression levels of the calcium-activated potassium channel KCa3.1, best known for its role in
immune cell calcium signaling, are elevated in activated microglia in both postmortem PD brains and in preclinical
models of PD. We further identified that disruption of either FYN or STAT1 dampens reactive microglia activation
responses via modulation of inflammatory mediators in aggregated αSyn (αSynagg)-stimulated primary microglia.
Importantly, the highly selective and orally active KCa3.1 inhibitor Senicapoc reduced neuroinflammation and
nigral dopamin(DA)ergic neurotoxicity in a preclinical mouse model of PD, suggesting that KCa3.1 plays a
multifaceted role by governing disease pathology. Despite these encouraging findings, the exact cellular
mechanisms by which KCa3.1 regulates microglial function in the context of synucleinopathy remain poorly
characterized. Herein, we propose three integrated aims to test the central hypothesis that KCa3.1 promotes
αSynagg-mediated progressive nigral DAergic neurodegenerative processes via activation of the microglial Fyn-
STAT1 signaling axis and that the in vivo inhibition of KCa3.1 restores microglial homeostasis and affords
DAergic neuroprotection in the context of synucleinopathy. In Aim-1, we will test the hypothesis that upregulation
of KCa3.1 induces the proinflammatory microglial activation phenotype and nigral DAergic neuronal loss in the
context of synucleinopathy. In Aim-2, we will test the hypothesis that the Fyn-STAT1 signaling axis drives
microglial responses to PD-like pathology in a KCa3.1-dependent manner. In Aim-3, we will test the hypothesis
that inhibiting KCa3.1 activation is efficacious in reducing reactive microglial activation and progressive PD-like
disease pathology. The proposed studies are innovative, utilizing a combination of transcriptomic profiling, RNA
in situ hybridization (ISH), imaging analysis, the RT QuIC assay for αSynagg seeding, CRISPR/Cas9 KCNN4
knockout (KO) mice, transgenic conditional KO mouse models, and electrophysiological recordings to test how
microglial KCa3.1 influences progressive neurodegenerative processes in PD. These studies address key
mechanistic aspects regarding the functional roles of KCa3.1 in PD pathogenesis and may aid in the identification
of new molecular determinants that can be targeted for slowing or halting PD progression and/or repurposing
Senicapoc for PD therapy.
1
摘要
最近的研究已经开始揭示小胶质细胞介导的神经炎症在帕金森病中的核心作用
疾病(PD)发病机制。越来越多的证据表明,小胶质细胞驱动的先天免疫可以进一步
增强有害的α-突触核蛋白(αSyn)聚集和进行性神经变性。然而,我们缺乏一个
深入了解调节αSyn-induced先天免疫的细胞机制。因此,我们认为,
识别响应帕金森病病理学调节小胶质细胞功能的信号传导机制,
导致PD的新型免疫调节疗法的发展。我们最近发现
和蛋白质表达水平的钙激活钾通道KCa3.1,最有名的作用,
免疫细胞钙信号传导,在死后PD脑和临床前PD脑中的活化小胶质细胞中升高。
PD模型我们进一步确定,FYN或STAT 1的破坏抑制了反应性小胶质细胞的激活,
通过调节聚集的αSyn(αSynagg)刺激的原代小胶质细胞中的炎症介质的反应。
重要的是,高选择性和口服活性的KCa3.1抑制剂Senicapoc减少了神经炎症,
黑质多巴胺(DA)能神经毒性在PD的临床前小鼠模型中,表明KCa 3.1起作用,
多方面的作用,通过管理疾病病理。尽管有这些令人鼓舞的发现,
在突触核蛋白病的背景下,KCa3.1调节小胶质细胞功能的机制仍然很差
表征了在此,我们提出了三个综合目标来检验KCa3.1促进
α Synag通过激活小胶质细胞Fyn介导的进行性黑质DA能神经退行性过程
STAT 1信号转导轴和KCa3.1的体内抑制恢复小胶质细胞稳态,
突触核蛋白病背景下DA能神经保护作用。在Aim-1中,我们将检验上调
KCa3.1的诱导促炎性小胶质细胞活化表型和黑质DA能神经元损失,
synucleinopathy突触核蛋白病在Aim-2中,我们将检验Fyn-STAT 1信号轴驱动
小胶质细胞以KCa3.1依赖性方式对PD样病理学的反应。在Aim-3中,我们将检验假设
抑制KCa3.1活化在减少反应性小胶质细胞活化和进行性PD样
疾病病理学拟议的研究是创新的,利用转录组学分析,RNA
原位杂交(ISH)、成像分析、αSynagg接种的RT QuIC测定、CRISPR/Cas9 KCNN 4
基因敲除(KO)小鼠、转基因条件性KO小鼠模型和电生理记录,以测试
小胶质细胞KCa 3.1影响PD中的进行性神经变性过程。这些研究解决了
关于KCa3.1在PD发病机制中的功能作用的机制方面,并可能有助于识别
新的分子决定因素,可以靶向减缓或停止PD进展和/或再利用
Senicapoc用于PD治疗。
1
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ARTHI KANTHASAMY其他文献
ARTHI KANTHASAMY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ARTHI KANTHASAMY', 18)}}的其他基金
Role of Prokineticin 2 in Metal Neurotoxicity
Prokineticin 2 在金属神经毒性中的作用
- 批准号:
10587599 - 财政年份:2023
- 资助金额:
$ 38.41万 - 项目类别:
Compensatory Mitochondrial Protective Mechanisms Against Oxidative Stress in PD
PD 中氧化应激的补偿性线粒体保护机制
- 批准号:
10609521 - 财政年份:2022
- 资助金额:
$ 38.41万 - 项目类别:
Compensatory Mitochondrial Protective Mechanisms Against Oxidative Stress in PD
PD 中氧化应激的补偿性线粒体保护机制
- 批准号:
10453241 - 财政年份:2022
- 资助金额:
$ 38.41万 - 项目类别:
The Role of KCa3.1 in Microglial function and in Parkinsons disease pathogenesis
KCa3.1 在小胶质细胞功能和帕金森病发病机制中的作用
- 批准号:
10631159 - 财政年份:2021
- 资助金额:
$ 38.41万 - 项目类别:
The Role of KCa3.1 in Microglial function and in Parkinsons disease pathogenesis
KCa3.1 在小胶质细胞功能和帕金森病发病机制中的作用
- 批准号:
10551785 - 财政年份:2021
- 资助金额:
$ 38.41万 - 项目类别:
Exosomes and Neuroinflammation in Parkinsons Disease
外泌体和帕金森病的神经炎症
- 批准号:
9207021 - 财政年份:2015
- 资助金额:
$ 38.41万 - 项目类别:
Prokineticin 2 and Neuroinflammatory Mechanisms
Prokineticin 2 和神经炎症机制
- 批准号:
8469590 - 财政年份:2012
- 资助金额:
$ 38.41万 - 项目类别:
Prokineticin 2 and Neuroinflammatory Mechanisms
Prokineticin 2 和神经炎症机制
- 批准号:
8273762 - 财政年份:2012
- 资助金额:
$ 38.41万 - 项目类别:
Prokineticin 2 and Neuroinflammatory Mechanisms
Prokineticin 2 和神经炎症机制
- 批准号:
8658161 - 财政年份:2012
- 资助金额:
$ 38.41万 - 项目类别:
Prokineticin 2 and Neuroinflammatory Mechanisms
Prokineticin 2 和神经炎症机制
- 批准号:
8843981 - 财政年份:2012
- 资助金额:
$ 38.41万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 38.41万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 38.41万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 38.41万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 38.41万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 38.41万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 38.41万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 38.41万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 38.41万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 38.41万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 38.41万 - 项目类别:
Research Grant